Stock Quote
Eli Lilly and Company (LLY) (NYSE Arca)
$36.80
23 Nov 2009
+0.57%
$36.80
--
5,129,145
$37.18
$36.63
$40.78
$27.21
0.82
6,056,107
LLY
More News
| Press Releases
| Key Developments
| Name | Current Position | Compensation |
|---|---|---|
| Lechleiter, John | Chairman of the Board, President, Chief Executive Officer | 12,978,215 |
| Rice, Derica | Chief Financial Officer, Senior Vice President | 5,206,142 |
| Deane, Frank | President - Manufacturing Operations | -- |
Profile
Eli Lilly and Company discovers, develops, manufactures and sells products in one business segment, pharmaceutical products. The Company also has an animal health business segment. It manufactures and distributes its products through owned or leased facilities in the United States, Puerto Rico and... Full Description
Company Address
Eli Lilly and Company
Lilly Corporate Center
Indianapolis IN 46285
P: +1317.2762000
F: +1317.2763492
Lilly Corporate Center
Indianapolis IN 46285
P: +1317.2762000
F: +1317.2763492
Analyst Research
Performance of Key Competitors
| Company | Price | Change |
|---|---|---|
| Johnson & Johnson | $62.69 | +0.38 |
| Pfizer Inc. | $18.53 | +0.17 |
| GlaxoSmithKline plc | £1,273.00 | -4.50 |
| LLY | Industry | |
|---|---|---|
| P/E(TTM) | -- | 6.90 |
| P/S(TTM) | 2.00 | 1.54 |
| ROI(TTM) | -1.02 | 6.18 |
| ROE(TTM) | -1.83 | 9.32 |
| Consensus Recommendation | Hold |
|---|---|
| EPS Est. (Current Period) | 1.17 |
| EPS Est. (Current Year) | 4.42 |
| Total Revenue | $5,562.00M |
| Net Income | $941.80M |
| EPS | $0.86 |
